Our fully integrated GxP services are driven by your assay requirements and delivered by our veteran scientists – collaboratively, accurately, and on time.
Biomarkers
Immunogenicity
Pharmacokinetics (PK)
Cell-Based Assays
Our team is comprised of recognized experts in effectively navigating complex and evolving opportunities for biotherapeutics innovation.
Biosimilars
Gene Therapy
Antibody Drug Conjugates (ADCs)
Immuno-oncology
Co-Hosted with GE Healthcare
The assessment of unwanted immunogenicity is a key parameter in the development process of biological protein drugs. In this webinar, BioAgilytix’s experts Dr. Arno Kromminga and Dr. Daniel Worms discuss aspects of when and how to use the Biacore™ T200 SPR System to obtain a deeper understanding of unwanted immunogenicity.
Explore the BioAgilytix way of thinking. Visit our Resource Center to learn more about our scientists’ expertise through case studies, blogs, industry articles and other scientific resources.
Quick links to our latest content offerings:
LinkedIn Company UpdatesJuly 18, 2019Immunogenicity Assessment Using the Biacore™ T200 SPR System
July 11, 2019510K Approved Assays vs. RUO Assays: Which Best Support Clinical Trial Biomarker Studies?
July 9, 2019BioAgilytix Completes New Campus Expansion at Its USA Headquarters
June 11, 2019BioAgilytix Welcomes Sean Blake to Leadership Team as Chief Information Officer
May 9, 2018Evaluating the Immunogenicity of Antibody–drug Conjugates
April 16, 2018Strategies for Development and Validation of Neutralizing Antibody Assays Supporting Biosimilars
Services
Platforms
Choose a Location to learn more about the premier bioanalytical services and solutions available at each of our advanced laboratories in the USA and Europe.
